+44 (0)1223 298875

Anti-Akt1 Antibody

Mouse monoclonal antibody to Akt1 from ABclonal (A0001).
Name: Anti-Akt1 Antibody
Description: Mouse monoclonal antibody to Akt1.
Applications: WB
Dilutions: WB: 1:500 - 1:1000.
Reactivity: Human
Immunogen: A synthetic peptide of human AKT1.
Protein Length: 480
Host: Mouse
Clonality: Monoclonal
Isotype: IgG
Conjugate: Unconjugated
Purification: Affinity purification.
Product Form: Liquid
Formulation: Supplied in Phosphate Buffered Saline, pH 7.30, with 0.02% Sodium Azide and 50% Glycerol.
Storage: Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Function: AKT1 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates. Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported. AKT is responsible of the regulation of glucose uptake by mediating insulin-induced translocation of the SLC2A4/GLUT4 glucose transporter to the cell surface. Phosphorylation of PTPN1 at 'Ser-50' negatively modulates its phosphatase activity preventing dephosphorylation of the insulin receptor and the attenuation of insulin signaling. Phosphorylation of TBC1D4 triggers the binding of this effector to inhibitory 14-3-3 proteins, which is required for insulin-stimulated glucose transport. AKT regulates also the storage of glucose in the form of glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at 'Ser-9', resulting in inhibition of its kinase activity. Phosphorylation of GSK3 isoforms by AKT is also thought to be one mechanism by which cell proliferation is driven. AKT regulates also cell survival via the phosphorylation of MAP3K5 (apoptosis signal-related kinase). Phosphorylation of 'Ser-83' decreases MAP3K5 kinase activity stimulated by oxidative stress and thereby prevents apoptosis. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating mTORC1 signaling and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1. AKT is involved in the phosphorylation of members of the FOXO factors (Forkhead family of transcription factors), leading to binding of 14-3-3 proteins and cytoplasmic localization. In particular, FOXO1 is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-319'. FOXO3 and FOXO4 are phosphorylated on equivalent sites. AKT has an important role in the regulation of NF-kappa-B-dependent gene transcription and positively regulates the activity of CREB1 (cyclic AMP (cAMP)-response element binding protein). The phosphorylation of CREB1 induces the binding of accessory proteins that are necessary for the transcription of pro-survival genes such as BCL2 and MCL1. AKT phosphorylates 'Ser-454' on ATP citrate lyase (ACLY), thereby potentially regulating ACLY activity and fatty acid synthesis. Activates the 3B isoform of cyclic nucleotide phosphodiesterase (PDE3B) via phosphorylation of 'Ser-273', resulting in reduced cyclic AMP levels and inhibition of lipolysis. Phosphorylates PIKFYVE on 'Ser-318', which results in increased PI(3)P-5 activity. The Rho GTPase-activating protein DLC1 is another substrate and its phosphorylation is implicated in the regulation cell proliferation and cell growth. AKT plays a role as key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I). AKT mediates the antiapoptotic effects of IGF-I. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. May be involved in the regulation of the placental development. Phosphorylates STK4/MST1 at 'Thr-120' and 'Thr-387' leading to inhibition of its: kinase activity, nuclear translocation, autophosphorylation and ability to phosphorylate FOXO3. Phosphorylates STK3/MST2 at 'Thr-117' and 'Thr-384' leading to inhibition of its: cleavage, kinase activity, autophosphorylation at Thr-180, binding to RASSF1 and nuclear translocation. Phosphorylates SRPK2 and enhances its kinase activity towards SRSF2 and ACIN1 and promotes its nuclear translocation. Phosphorylates RAF1 at 'Ser-259' and negatively regulates its activity. Phosphorylation of BAD stimulates its pro-apoptotic activity. Phosphorylates KAT6A at 'Thr-369' and this phosphorylation inhibits the interaction of KAT6A with PML and negatively regulates its acetylation activity towards p53/TP53.
Tissue Specificity: Expressed in prostate cancer and levels increase from the normal to the malignant state (at protein level). Expressed in all human cell types so far analyzed. The Tyr-176 phosphorylated form shows a significant increase in expression in breast cancers during the progressive stages i.e. normal to hyperplasia (ADH), ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC) and lymph node metastatic (LNMM) stages.
Involvement in Disease: Breast cancer: A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.

Colorectal cancer: A complex disease characterized by malignant lesions arising from the inner wall of the large intestine (the colon) and the rectum. Genetic alterations are often associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Risk factors for cancer of the colon and rectum include colon polyps, long-standing ulcerative colitis, and genetic family history.

Proteus syndrome: A highly variable, severe disorder of asymmetric and disproportionate overgrowth of body parts, connective tissue nevi, epidermal nevi, dysregulated adipose tissue, and vascular malformations. Many features of Proteus syndrome overlap with other overgrowth syndromes.

Cowden syndrome 6: A form of Cowden syndrome, a hamartomatous polyposis syndrome with age-related penetrance. Cowden syndrome is characterized by hamartomatous lesions affecting derivatives of ectodermal, mesodermal and endodermal layers, macrocephaly, facial trichilemmomas (benign tumors of the hair follicle infundibulum), acral keratoses, papillomatous papules, and elevated risk for development of several types of malignancy, particularly breast carcinoma in women and thyroid carcinoma in both men and women. Colon cancer and renal cell carcinoma have also been reported. Hamartomas can be found in virtually every organ, but most commonly in the skin, gastrointestinal tract, breast and thyroid.
Sequence Similarities: Belongs to the protein kinase superfamily. AGC Ser/Thr protein kinase family. RAC subfamily.
Post-Translational Modification: O-GlcNAcylation at Thr-305 and Thr-312 inhibits activating phosphorylation at Thr-308 via disrupting the interaction between AKT1 and PDPK1. O-GlcNAcylation at Ser-473 also probably interferes with phosphorylation at this site.
Cellular Location: Cytoplasm. Nucleus. Cell membrane.

Nucleus after activation by integrin-linked protein kinase 1 (ILK1). Nuclear translocation is enhanced by interaction with TCL1A. Phosphorylation on Tyr-176 by TNK2 results in its localization to the cell membrane where it is targeted for further phosphorylations on Thr-308 and Ser-473 leading to its activation and the activated form translocates to the nucleus. Colocalizes with WDFY2 in intracellular vesicles (PubMed:16792529).
UniProt: P31749
Gene ID: 207
Synonyms: AKT Antibody
AKT 1 Antibody
AKT1_HUMAN Antibody
AKT2 Antibody
AKT3 Antibody
MGC99656 Antibody
pan-AKT Antibody
PKB Antibody
PKB alpha Antibody
PKB beta Antibody
PKB-ALPHA Antibody
PKBalpha Antibody
PRKBA Antibody
PRKBB Antibody
PRKBG Antibody
Protein kinase B Antibody
Protein Kinase B Alpha Antibody
Protein kinase B beta Antibody
Protein kinase B gamma Antibody
Proto-oncogene c-Akt Antibody
RAC Antibody
RAC Alpha Antibody
RAC gamma Antibody
RAC PK alpha Antibody
RAC PK beta Antibody
RAC PK gamma Antibody
RAC-alpha serine/threonine-protein kinase Antibody
RAC-PK-alpha Antibody
STK2 Antibody
Information: Target information shown above is from the UniProt Consortium.
Western blot analysis of extracts of HeLa cell line, using AKT1 antibody.
Please Note: All batches are extensively validated and are guaranteed to work as specified, however, QC data is not necessarily from the current lot on sale.
Total Citations (71)
Description: Rabbit polyclonal antibody to AKT (phospho-S473)
Application: WB, IHC
Host: Rabbit
Reactivity: Human, Mouse, Rat
Immunogen: Synthetic phosphopeptide derived from human AKT1 around the phosphorylation site of Serine 473.

£175 – £302

Total Citations (43)
Description: Rabbit polyclonal antibody to AKT (A444)
Application: WB, IHC
Host: Rabbit
Reactivity: Human, Mouse, Rat
Immunogen: Synthetic peptide, corresponding to amino acids 420-470 of Human AKT1.

£165 – £283

Total Citations (34)
Description: Rabbit polyclonal antibody to AKT (phospho-T308)
Application: WB, IHC
Host: Rabbit
Reactivity: Human, Mouse, Rat
Immunogen: Synthetic phosphopeptide derived from human AKT1 around the phosphorylation site of Threonine 308.

£175 – £302

Total Citations (33)
Description: Rabbit polyclonal antibody to AKT
Application: WB, IHC
Host: Rabbit
Reactivity: Human, Mouse, Rat
Immunogen: Recombinant full length Human AKT1.

£165 – £283

Please Note: Anti-Akt1 Antibody is for research use only. It is not intended for diagnostic or therapeutic use.
Antibodies.com | A0001
Size Price Quantity
100µl £243
200µl £372

or
Request a quotation
Contact Us Directly
  • call icon + 44 (0)1223 298 875
  • + 44 (0)1223 281 447
  • email icon info@antibodies.com
Product Quality
  • guarantee icon
  • We promise guaranteed product quality
  • and expert customer service.
Lead Time: Currently 4-6 Days
Shipping Information
  • £20 to United Kingdom
  • £35 to Europe